|
|
|
|
|
|
|
|
|
23.06.26 - 11:36
|
Lilly and BioArctic sign deal to develop neurodegenerative therapy (PBR)
|
|
|
The partnership will combine BioArctic's BrainTransporter technology with an unidentified Lilly drug candidate. BioArctic is set to receive a $30m upfront payment. If the new product progresses successfully,
The post Lilly and BioArctic sign deal to develop neurodegenerative therapy appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
29.05.26 - 18:32
|
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026 (Cision)
|
|
|
Stockholm, May 29, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 5,000 stock options of series 2019/2028.
As of May 29, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,724,485 shares, of which 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten...
|
|
|
28.05.26 - 19:42
|
Bulletin from the Annual General Meeting in BioArctic AB (publ) (PR Newswire)
|
|
|
STOCKHOLM, May 28, 2026 /PRNewswire/ -- Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made. Adoption of the income statement and the balance sheet: allocation of result and determination of the......
|
|
|
|
|
20.05.26 - 09:42
|
BioArctic Interim Report for the period January - March 2026 (PR Newswire)
|
|
|
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded......
|
|
|
20.05.26 - 09:36
|
BioArctic Interim Report for the period January - March 2026 (PR Newswire)
|
|
|
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded......
|
|
|
|
|
|
|
15.05.26 - 08:36
|
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 – March 2027) (Cision)
|
|
|
Stockholm, Sweden, May 15, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4 billion) for their fiscal year (FY) 2026 (April 2026 through March 2027), corresponding to a 63 percent growth compared to the previous year. This would generate approximately SEK 880 M in royalty to BioArctic during the same period.
Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor...
|
|
|
|
|
13.05.26 - 08:37
|
Invitation to presentation of BioArctic′s first quarter report for January – March 2026 on May 20 at 9:30 a.m. CET (Cision)
|
|
|
Stockholm, Sweden, May 13, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's first quarter report for January – March 2026 on Wednesday, May 20, 2026, at 8:00 a.m. CET.
In conjunction with the report, BioArctic invites investors, analysts and media to a webcast (in English) on May 20, at 9:30 a.m CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the first quarter report, followed by a Q&A session.
If you wish to participate via the webcast, please use the link below, where you will be able to...
|
|
|
08.05.26 - 09:06
|
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S. (Cision)
|
|
|
Stockholm, Sweden, May 8, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi® Iqlik™, as a starting dose for the treatment of early Alzheimer's disease. The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026.
As part of the ongoing review process, the agency requested additional information and has...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
